Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Rockefeller-Led Team Launches Initiative to Study COVID-19 Genetic Vulnerability

Rockefeller-Led Team Launches Initiative to Study COVID-19 Genetic Vulnerability

Mar 26, 2020
|
staff reporter

NEW YORK – An international team of researchers led by a group at Rockefeller University has launched a project to determine if inborn errors of immunity (IEI) can cause life-threatening COVID-19 in previously healthy younger patients.

The group believes that the project will identify genetic pathways involved in COVID-19 development in patients that get severely ill and lead to new preventative and therapeutic strategies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Plans Out

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

CovidNudge Numbers

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

Science Papers Propose Group to Discuss Genome-Editing Tools, Markers of Diabetes Drug Response, More

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

Not Counting These

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Infectious Disease

  1. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  2. Genetics Testing Firm Prenetics Receives $15M Investment From Apis Partners, Alibaba

  3. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  4. Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

  5. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.